RxDoctor Payments Data

Aaron Geller, MD

Clinical Neurophysiology · Aurora, CONPI 1447516828

Payments from drug & device makers

$1,310in general payments, 2019–2025

Across 52 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$729
  • Supernus Pharmaceuticals, Inc.$293
  • Jazz Pharmaceuticals Inc.$60
  • UCB, Inc.$58
  • Eisai Inc.$51
  • Sunovion Pharmaceuticals Inc.$31
  • plus $87 from 5 others

What the payments were for

  • Food & beverage$1,310100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Coloradoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$27,287
Medicare patients
109
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate40$63,544
BriviactBrivaracetam21$51,728
Clobazam25$22,392
Lacosamide95$17,009
Levetiracetam96$4,921
Carbamazepine ErCarbamazepine11$3,889
Lamotrigine97$3,672
Lamotrigine ErLamotrigine22$2,617
Carbamazepine30$1,787
Zonisamide33$1,575
Divalproex Sodium ErDivalproex Sodium18$1,435
Phenytoin Sodium Extended25$721
Divalproex Sodium18$550
Phenobarbital29$421
Phenytoin13$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$729$63,54440 claims
UCB, Inc.Briviact$58$51,72821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Coloradoon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Aurora

Where these figures come from

Is this you, or does something look wrong? →